A case of sequential medical therapy for advanced ureteral cancer in Li-Fraumeni syndrome.
Li–Fraumeni syndrome
TP53 pathogenic variant
advanced urothelial cancer
avelumab
immune checkpoint inhibitor
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
11
04
2023
accepted:
28
06
2023
medline:
5
9
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
epublish
Résumé
Li-Fraumeni syndrome, an autosomal dominant cancer predisposition syndrome caused by a pathogenic variant of A 73 years-old female patient, who had been diagnosed genetically as Li-Fraumeni syndrome; suffered from chondrosarcoma in the left pelvic joint, bilateral breast cancer, endometrial cancer, gastric cancer, and colon cancer in her history. She was diagnosed as unresectable advanced urothelial cancer during continuous magnetic resonance imaging surveillance, underwent avelumab maintenance therapy after the combination of gemcitabine and cisplatin chemotherapy. The efficacies of gemcitabine and cisplatin chemotherapy and avelumab maintenance therapy were good. We report an advanced urothelial cancer in a patient with Li-Fraumeni syndrome who demonstrated good efficacies to sequential medical therapy.
Identifiants
pubmed: 37667764
doi: 10.1002/iju5.12607
pii: IJU512607
pmc: PMC10475342
doi:
Types de publication
Case Reports
Langues
eng
Pagination
286-289Informations de copyright
© 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Int J Clin Oncol. 2021 Dec;26(12):2161-2178
pubmed: 34633580
Int J Mol Sci. 2020 Jun 08;21(11):
pubmed: 32521648
Cancer Sci. 2021 May 1;:
pubmed: 33932062
Int J Clin Oncol. 2018 Aug;23(4):599-607
pubmed: 29556919
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
Cancers (Basel). 2022 Jul 27;14(15):
pubmed: 35954327
Cancer Cell. 2021 Dec 13;39(12):1594-1609.e12
pubmed: 34767762
Int J Clin Oncol. 2008 Aug;13(4):282-6
pubmed: 18704627
Front Oncol. 2022 Apr 04;12:746922
pubmed: 35444946
Lancet Oncol. 2011 Jun;12(6):559-67
pubmed: 21601526
Eur J Hum Genet. 2020 Oct;28(10):1379-1386
pubmed: 32457520
Front Biosci (Landmark Ed). 2022 Mar 8;27(3):88
pubmed: 35345320
Urology. 2004 May;63(5):989-93
pubmed: 15135005
Cancer Med. 2021 Apr;10(7):2216-2231
pubmed: 33655698